• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Hookipa Pharma Inc (NQ: HOOK )

    3.590 -0.110 (-2.97%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 12, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Hookipa Pharma Inc

    < Previous 1 2 Next >
    HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
    Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell... 
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
    Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
    Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm
    From Kaskela Law LLC
    Via Business Wire
    HOOKIPA Pharma Announces Board of Directors Changes
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
    Via AB Newswire
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
    From HOOKIPA Pharma Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.